A randomized trial comparing the efficacy and safety of intravitreal @entity2713 with observation to treat @entity1018 associated with XXXX secondary to central @entity2994 : the Standard Care vs Corticosteroid for @entity2994 (SCORE) study report 5.

@entity1018 @entity1 @entity231 @entity2994 @entity1103 @entity2790 @entity2713
OBJECTIVE: To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal @entity2713 with observation for eyes with @entity1018 associated with @entity1103 secondary to perfused central @entity2994 (CRVO). METHODS: Multicenter, randomized, clinical trial of 271 @entity1 . MAIN OUTCOME MEASURE: Gain in visual acuity letter score of 15 or more from baseline to month 12. RESULTS: Seven percent, 27%, and 26% of @entity1 achieved the primary outcome in the observation, 1-mg, and 4-mg groups, respectively. The odds of achieving the primary outcome were 5.0 times greater in the 1-mg group than the observation group (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.8-14.1; P = .001) and 5.0 times greater in 4-mg group than the observation group (OR, 5.0; 95% CI, 1.8-14.4; P = .001); there was no difference identified between the 1-mg and 4-mg groups (OR, 1.0; 95% CI, 0.5-2.1; P = .97). The rates of @entity2790 and @entity231 were similar for the observation and 1-mg groups, but higher in the 4-mg group. CONCLUSIONS: Intravitreal @entity2713 is superior to observation for treating @entity1018 associated with @entity1103 secondary to CRVO in @entity1 who have characteristics similar to those in the SCORE-CRVO trial. The 1-mg dose has a safety profile superior to that of the 4-mg dose. Application to Clinical Practice Intravitreal @entity2713 in a 1-mg dose, following the retreatment criteria applied in the SCORE Study, should be considered for up to 1 year, and possibly 2 years, for @entity1 with characteristics similar to those in the SCORE-CRVO trial. Trial Registration clinicaltrials.gov Identifier: NCT00105027.
